In a breakthrough for oncology, Johnson & Johnson has announced promising early results from a Phase 1b clinical trial for its second-generation CAR T-cell therapy, JNJ-90014496 (also referred to as JNJ-4496). The treatment has been demonstrated to have a strong success rate for treating patients who have relapsed or are refractory to large B-cell lymphoma (R/R LBCL), a particularly aggressive and challenging-to-treat type of cancer.
Dual CAR-T therapy for lymphoma
At the center of this new therapy is its novel dual-targeting strategy. In contrast to some current CAR T-cell treatments that focus on one antigen, JNJ-4496 is designed to recognize and target malignant B-cells by targeting two separate antigens: CD19 and CD20. This two-pronged approach aims to produce a more robust and more resilient response, and most importantly, to deal with the problem of treatment resistance, a significant barrier in those patients whose disease has recurred or no longer responds to earlier treatments.
Johnson & Johnson CAR-T Results
The early-stage trial has shown strong evidence of the treatment’s success. Of patients who were given the dose that will be used in the Phase 2 trial, a staggering 75 to 80 percent experienced a complete response. What this implies is that in most of these patients, all evidence of their cancer vanished after treatment.
Safety Profile
Aside from its efficacy, JNJ-4496 has also exhibited a good safety profile. One of the biggest issues with CAR T-cell treatments is that it can cause severe side effects, most notably cytokine release syndrome (CRS). Praise be to the researchers, then, that this study saw no cases of Grade 3 or 4 CRS, the most extreme cases of this inflammatory condition. That optimistic safety data only reinforces the idea that the treatment could be more tolerable for patients.
Future
These initial findings indicate that JNJ-4496 may be a significant advance in the treatment of large B-cell lymphoma. For those patients who have no remaining treatment options available to them, this dual-targeting CAR T-cell therapy provides a glimmer of hope. Although preliminary, these results come from a high complete response rate and an acceptable safety profile that situate JNJ-4496 as a potentially game-changing treatment for this serious disease. Additional research in bigger clinical studies will be important to validate these encouraging findings.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
